What is Astellas Pharma?
Headquartered in Tokyo, Japan, Astellas Pharma operates as a sophisticated multinational entity dedicated to the manufacturing, marketing, import, and export of high-value pharmaceutical products. The company maintains a critical market position by leveraging advanced biotechnology and clinical research to address unmet medical needs. By integrating complex supply chain logistics with rigorous regulatory compliance, Astellas Pharma has established itself as a cornerstone of the global healthcare infrastructure, consistently delivering therapeutic innovations across diverse medical categories.
How much funding has Astellas Pharma raised?
Astellas Pharma has raised a total of $212.5M across 4 funding rounds:
Series A
$30M
Series B
$42.5M
Series C
$65M
Stock Offering
$75M
Series A (2013): $30M with participation from OrbiMed, Versant Ventures, and 5AM Ventures
Series B (2014): $42.5M led by Sofinnova Ventures, 5AM Ventures, Venrock Associates, OrbiMed, Deerfield Management, and Versant Ventures
Series C (2015): $65M supported by 5AM Ventures, Redmile Group, Deerfield Management, RA Capital Management, Cormorant Asset Management, OrbiMed, Cowen, Sofinnova Ventures, Versant Ventures, Venrock Associates, and Foresite Capital
Stock Issuance/Offering (2016): $75M, investors not publicly disclosed
Key Investors in Astellas Pharma
OrbiMed
A premier healthcare-focused investment firm that provides capital to companies across the entire spectrum of the life sciences industry.
Versant Ventures
A leading healthcare venture capital firm committed to helping entrepreneurs build companies that transform patients' lives through innovative medical breakthroughs.
5AM Ventures
An early-stage venture capital firm specializing in the life sciences sector, focused on building next-generation pharmaceutical and biotechnology companies.
What's next for Astellas Pharma?
Looking ahead, the recent infusion of capital is expected to accelerate the company's strategic initiatives, particularly in the realms of precision medicine and digital health integration. As Astellas Pharma navigates the evolving landscape of global drug development, the focus remains on optimizing operational efficiencies and expanding its footprint in emerging markets. This major strategic investment provides the necessary liquidity to pursue aggressive M&A activity and internal innovation, ensuring the firm remains at the forefront of the pharmaceutical industry's competitive evolution.
See full Astellas Pharma company page
